Publications by authors named "Jan Sterz"

Claim this Profile
T
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
Britta Lamottke, Martin Kaiser, Maren Mieth, Ulrike Heider, Zhenhai Gao, Jan Sterz

Eur J Haematol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
Jan Sterz, Christian Jakob, Ulrike Kuckelkorn, Ulrike Heider, Maren Mieth

Eur J Haematol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum levels of total-RANKL in multiple myeloma.
Christian Jakob, Andrea Goerke, Evangelos Terpos, Jan Sterz, Ulrike Heider

Clin Lymphoma Myeloma· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential of proteasome inhibitors in cancer therapy.
Jan Sterz, Ivana von Metzler, Jens-Claus Hahne, Britta Lamottke, Jessica Rademacher

Expert Opin Investig Drugs· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Ulrike Heider, Ivana von Metzler, Martin Kaiser, Marleen Rosche, Jan Sterz

Eur J Haematol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
Monica Hecht, Ulrike Heider, Martin Kaiser, Ivana von Metzler, Jan Sterz

Br J Haematol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
Christian Jakob, Karl Egerer, Peter Liebisch, Seval Türkmen, Ivana Zavrski, Jan Sterz

Blood· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
Jan Eucker, Jan Sterz, Holger Krebbel, Ivana Zavrski, Martin Kaiser

Anticancer Drugs· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiogenesis in multiple myeloma.
Christian Jakob, Jan Sterz, Ivana Zavrski, Ulrike Heider, Lorenz Kleeberg

Eur J Cancer· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
Martin Kaiser, Ivana Zavrski, Jan Sterz, Christian Jakob, Claudia Fleissner

Haematologica· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Ulrike Heider, Martin Kaiser, Jan Sterz, Ivana Zavrski, Christian Jakob

Eur J Haematol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis